内科理论与实践 ›› 2023, Vol. 18 ›› Issue (05): 372-376.doi: 10.16138/j.1673-6087.2023.05.014
• 综述 • 上一篇
王翠, 姜国刚, 崔晓利
收稿日期:2023-03-09
出版日期:2023-10-30
发布日期:2024-01-25
基金资助:WANG Cui, JIANG Guogang, CUI Xiaoli
Received:2023-03-09
Online:2023-10-30
Published:2024-01-25
中图分类号:
王翠, 姜国刚, 崔晓利. 痰液分析对慢性阻塞性肺疾病诊疗及病情评估的研究进展[J]. 内科理论与实践, 2023, 18(05): 372-376.
WANG Cui, JIANG Guogang, CUI Xiaoli. Research progress of sputum analysis in the diagnosis, treatment and assessment of chronic obstructive pulmonary disease[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(05): 372-376.
| [8] |
Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chro-nic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2021, 147(1): 158-167.
doi: 10.1016/j.jaci.2020.02.040 URL |
| [9] |
Armitage MN, Spittle DA, Turner AM. A systematic review and meta-analysis of the prevalence and impact of pulmonary bacterial colonisation in stable state chronic obstructive pulmonary disease(COPD)[J]. Biomedicines, 2021, 10(1): 81.
doi: 10.3390/biomedicines10010081 URL |
| [10] | 翟红瑞, 罗松平, 林磊, 等. 无创-有创机械通气序贯性治疗慢性阻塞性肺疾病急性加重中切换时机的临床研究[J]. 中华危重病急救医学, 2020, 32(2): 161-165. |
| [11] |
Liu Y, Zeng S, Li Y, et al. The effect of acupoint application of traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease: a protocol for systematic review and meta-analysis[J]. Medicine, 2020, 99(43): e22730.
doi: 10.1097/MD.0000000000022730 URL |
| [12] | Pooni RS, Corbett R. serum urate reduction and its effect on the progression of chronic kidney disease[J]. Clin Med (Lond), 2020, 20(5): 448. |
| [13] |
Karnaushkina MA, Fedosenko SV, Danilov RS, et al. Eosinophilic cationic protein as a non-invasive marker of the nature of inflammatory response in patients with chronic obstructive pulmonary disease[J]. Bulletin of Siberian Medicine, 2020, 19(1): 59-66.
doi: 10.20538/1682-0363-2020-19-1 URL |
| [14] |
Zhang J, He X, Hu J, et al. Failure of early extubation among cases of coronavirus disease-19 respiratory failure: case report and clinical experience[J]. Medicine, 2020, 99(27): e20843.
doi: 10.1097/MD.0000000000020843 URL |
| [15] |
Wu JJ, Zhang YX, Xu HR, et al. Effect of acupoint application on T lymphocyte subsets in patients with chronic obstructive pulmonary disease[J]. Medicine, 2020, 99(16): e19537.
doi: 10.1097/MD.0000000000019537 URL |
| [16] |
Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?[J]. Proc Am Thorac Soc, 2006, 3(8): 687-690.
doi: 10.1513/pats.200605-105SF URL |
| [17] |
Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J]. PLoS One, 2012, 7(10): e47305.
doi: 10.1371/journal.pone.0047305 URL |
| [18] |
Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2021, 147(1): 158-167.
doi: 10.1016/j.jaci.2020.02.040 pmid: 32353489 |
| [19] | Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort[J]. RRespir Res, 2020 Mar 30; 21(1): 77. |
| [20] |
Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations[J]. Am J Respir Crit Care Med, 2021, 203(12): 1488-1502.
doi: 10.1164/rccm.202009-3448OC URL |
| [21] |
Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT[J]. Health Technol Assess, 2020, 24(15): 1-108.
doi: 10.3310/hta24150 pmid: 32202490 |
| [22] |
Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease[J]. Thorax, 2012, 67(5): 456-63.
doi: 10.1136/thoraxjnl-2011-201183 pmid: 22318161 |
| [23] |
Einarsson GG, Comer DM, McIlreavey L, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers[J]. Thorax, 2016, 71(9): 795-803.
doi: 10.1136/thoraxjnl-2015-207235 pmid: 27146202 |
| [24] |
Shukla SD, Budden KF, Neal R, et al. Microbiome effects on immunity, health and disease in the lung[J]. Clin Transl Immunology, 2017, 6(3): e133.
doi: 10.1038/cti.2017.6 URL |
| [25] |
Aguirre E, Galiana A, Mira A, et al. Analysis of microbiota in stable patients with chronic obstructive pulmonary disease[J]. APMIS, 2015, 123(5): 427-432.
doi: 10.1111/apm.12363 pmid: 25858184 |
| [26] |
Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease[J]. J Clin Microbiol, 2014, 52(8): 2813-2823.
doi: 10.1128/JCM.00035-14 pmid: 24850358 |
| [27] |
Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD[J]. PLoS One, 2011, 6(2): e16384.
doi: 10.1371/journal.pone.0016384 URL |
| [28] |
Kurai D, Saraya T, Ishii H, et al. Virus-induced exacerbations in asthma and COPD[J]. Front Microbiol, 2013, 4:293.
doi: 10.3389/fmicb.2013.00293 pmid: 24098299 |
| [29] |
Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J]. PLoS One, 2012, 7(10): e47305.
doi: 10.1371/journal.pone.0047305 URL |
| [30] |
Leung JM, Tiew PY, Mac Aogáin M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD[J]. Respirology, 2017, 22(4):634-650.
doi: 10.1111/resp.13032 pmid: 28342288 |
| [31] | Sethi S. Chronic obstructive pulmonary disease and infection. Disruption of the microbiome?[J]. Ann Am Thorac Soc, 2014, 11 Suppl 1: S43-S47. |
| [32] |
Ergan B, Topeli A. Antibiotic decision in severe chronic obstructive pulmonary disease exacerbations[J]. Respiration, 2017, 94(1): 75.
doi: 10.1159/000472719 pmid: 28434001 |
| [33] | Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful?[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9: 163-77. |
| [34] |
Goeminne PC, Vanfleteren LEGW. Bronchiectasis economics: spend money to save money[J]. Respiration, 2018, 96(5): 399-402.
doi: 10.1159/000490550 pmid: 30041195 |
| [35] | Halfawy AA, Abdelhafiz H, Kamal E, et al. Characteristic features and percentage of asthma chronic obstructive pulmonary disease overlap among patients with obstructive airway diseases[J]. Egypt J Chest Dis Tuberc, 2020, 67(4): 356-360. |
| [36] |
Meng W, Cao X, Sun W, et al. A functional polymorphism at the miR-491-5p binding site in the 3’-untranslated region of the MMP-9 gene increases the risk of developing ventilator-associated pneumonia[J]. Int J Mol Med, 2021, 48(6): 217.
doi: 10.3892/ijmm URL |
| [37] |
Venegas C, Zhao N, Ho T, et al. Sputum inflammometry to manage chronic obstructive pulmonary disease exacerbations: beyond guidelines[J]. Tuberc Respir Dis (Seoul), 2020, 83(3):175-184.
doi: 10.4046/trd.2020.0033 URL |
| [38] |
Zhang F, Zhong Y, Qin Z, et al. Effect of muscle training on dyspnea in patients with chronic obstructive pulmonary disease[J]. Medicine (Baltimore), 2021, 100(9):e24930.
doi: 10.1097/MD.0000000000024930 URL |
| [39] |
Huang J, Bian Y, Zhao Y, et al. The impact of depression and anxiety on chronic obstructive pulmonary disease acute exacerbations[J]. J Affect Disord, 2021, 281:147-152.
doi: 10.1016/j.jad.2020.12.030 URL |
| [40] |
Kumar PA, Sreekanth AS. A study on overview of asthma-chronic obstructive pulmonary disease overlaps among patients with obstructive airway diseases[J]. IJIRM, 2021, 6(2): 117-120.
doi: 10.18231/ijirm URL |
| [41] |
Park MH, Kim MJ, Kim AJ, et al. Helmet-based noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease[J]. World J Clin Cases, 2020, 8(10): 1939-1943.
doi: 10.12998/wjcc.v8.i10.1939 pmid: 32518784 |
| [1] |
Der Mesropian PJ, Shaikh G, Beers KH, et al. Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria[J]. J Investig Med, 2021, 69(5): 1035-1043.
doi: 10.1136/jim-2020-001702 URL |
| [2] |
Afsar B, Afsar RE, Copur S, et al. The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence[J]. Br J Nutr, 2021, 125(11): 1201-1214.
doi: 10.1017/S000711452000358X URL |
| [42] | King AH, Kwan S, Kim A, et al. Effect of the neutrophil/lymphocyte ratio on outcome after carotid endarterectomy and carotid artery disease progression[J]. J Am Coll Surg, 2020, 231(4): S343. |
| [43] |
Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2003, 167(8): 1090-1095.
doi: 10.1164/rccm.200210-1179OC URL |
| [44] |
Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease[J]. N Engl J Med, 2002, 347(7): 465-471.
doi: 10.1056/NEJMoa012561 URL |
| [45] |
Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2011, 184(5): 507-513.
doi: 10.1164/rccm.201103-0405PP URL |
| [46] |
Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD[J]. Thorax, 2012, 67(12): 1075-1080.
doi: 10.1136/thoraxjnl-2012-201924 pmid: 22863758 |
| [47] |
Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease[J]. J Clin Microbiol, 2014, 52(8): 2813-2823.
doi: 10.1128/JCM.00035-14 pmid: 24850358 |
| [48] |
Pragman AA, Knutson KA, Gould TJ, et al. Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study[J]. Respir Res, 2019, 20(1): 114.
doi: 10.1186/s12931-019-1080-4 |
| [49] |
Wisor JP, Holmedahl NH, Saxvig IW, et al. Effect of dietary nitrate supplementation on sleep in chronic obstructive pulmonary disease patients[J]. Nat Sci Sleep, 2021, 13: 435-446.
doi: 10.2147/NSS.S279395 pmid: 33790676 |
| [3] |
Wang C, Xu J, Yang L, et al. China pulmonary health study group[J]. Lancet, 2018, 391(101311):1706-1717.
doi: 10.1016/S0140-6736(18)30841-9 URL |
| [4] |
O’Donnell DE, Parker CM. COPD exacerbations 3: pathophysiology[J]. Thorax, 2006, 61(4): 354-361.
doi: 10.1136/thx.2005.041830 URL |
| [5] |
Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease[J]. Eur Respir J, 2007, 29(6): 1224-1238.
doi: 10.1183/09031936.00109906 pmid: 17540785 |
| [6] | 刘奇, 陆欢, 单梦田, 等. 头罩无创通气在慢性阻塞性肺疾病急性加重合并呼吸衰竭患者中的应用[J]. 中华危重病急救医学, 2020, 32(1): 14-19. |
| [50] |
Muggeo A, Perotin JM, Brisebarre A, et al. Extended bacteria culture-based clustering identifies a phenotype associating increased cough and enterobacterales in stable chronic obstructive pulmonary disease[J]. Front Microbiol, 2021, 12: 781797.
doi: 10.3389/fmicb.2021.781797 URL |
| [51] |
Onuska KM. The dual role of microglia in the progression of Alzheimer’s disease[J]. J Neurosci, 2020, 40(8):1608-1610.
doi: 10.1523/JNEUROSCI.2594-19.2020 pmid: 32075949 |
| [52] |
Ra SW, Kwon YS, Yoon SH, et al. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(4): 1424-1432.
doi: 10.1111/crj.12671 pmid: 28756637 |
| [53] |
Messous S, Grissa MH, Beltaief K, et al. Bacteriology of acute exacerbations of chronic obstructive pulmonary disease in Tunisia[J]. Rev Mal Respir, 2018, 35(1): 36-47.
doi: S0761-8425(17)30220-6 pmid: 29395563 |
| [7] |
Miravitlles M, Alcázar B, Soler-Cataluña XX. The concept of control in chronic obstructive pulmonary disease: development of the criteria and validation for use in cli-nical practice[J]. Russian Pulmonology, 2020, 30(2): 135-141.
doi: 10.18093/0869-0189-2020-30-2 URL |
| [54] |
Szylińska A, Kotfis K, Listewnik M, et al. The burden of chronic obstructive pulmonary disease in open heart surgery-a retrospective cohort analysis of postoperative complications[J]. Medicine (Baltimore), 2020, 99(13):e19675.
doi: 10.1097/MD.0000000000019675 URL |
| [55] | Arafa MA. Sputum bacteriology in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Egypt J Hos Med, 2021, 84(1): 2510-2515. |
| [56] |
Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations[J]. Am J Respir Crit Care Med, 2021, 203(12): 1488-1502.
doi: 10.1164/rccm.202009-3448OC URL |
| [57] |
Kim EK, Singh D, Park JH, et al. Impact of body mass index change on the prognosis of chronic obstructive pulmonary disease[J]. Respiration, 2020, 99(11): 943-953.
doi: 10.1159/000511022 pmid: 33264797 |
| [58] |
Singh D, Lea S, Mathioudakis AG. Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease[J]. Drugs, 2021, 81(16): 1821-1830.
doi: 10.1007/s40265-021-01616-9 pmid: 34731461 |
| [59] |
Leitao Filho FS, Takiguchi H, Akata K, et al. Effects of inhaled corticosteroid/long-acting β2-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 204(10): 1143-1152.
doi: 10.1164/rccm.202102-0289OC URL |
| [60] |
Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease[J]. Respir Res, 2019, 20(1): 113.
doi: 10.1186/s12931-019-1085-z |
| [61] |
Meteran H, Thomsen SF, Miller MR, et al. Impact of the spirometric definition on comorbidities in chronic obstructive pulmonary disease[J]. Respir Med, 2021, 184:106399.
doi: 10.1016/j.rmed.2021.106399 URL |
| [1] | 孙娴雯, 李庆云. 关注保留比率的肺功能减损（PRISm）的慢性阻塞性肺疾病表型[J]. 诊断学理论与实践, 2023, 22(03): 234-237. |
| [2] | 沈宏华, 许轶明, 张音, 任蕾, 陈锐. 慢性阻塞性肺疾病-阻塞性睡眠呼吸暂停重叠综合征的研究进展[J]. 内科理论与实践, 2023, 18(02): 111-116. |
| [3] | 刘泓源 顾豪 杨希 胡丽 徐梓安 陈辉 林晓曦. 一种基于DNA测序结果的静脉/淋巴管畸形新基因分型[J]. 组织工程与重建外科杂志, 2022, 18(3): 209-. |
| [4] | 张璐璐, 武倩男, 霍如婕, 田新瑞. 微RNA-206与肺部疾病的研究进展[J]. 内科理论与实践, 2022, 17(05): 413-417. |
| [5] | 孙娴雯, 李庆云. 新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读[J]. 诊断学理论与实践, 2022, 21(01): 32-37. |
| [6] | 仇丽雯, 许轶明, 张音, 沈宏华, 陈慎. 抗阻联合有氧训练对老年慢性阻塞性肺疾病患者运动能力的疗效[J]. 内科理论与实践, 2022, 17(01): 78-83. |
| [7] | 刘礼银, 胡系伟, 杨然. 远程医疗在慢性阻塞性肺疾病患者肺康复中的应用价值[J]. 内科理论与实践, 2022, 17(01): 97-101. |
| [8] | 李庆云, 孙娴雯. 慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读[J]. 诊断学理论与实践, 2021, 20(01): 43-47. |
| [9] | 李庆云, 孙娴雯. 细化稳定期COPD管理流程和随访策略：2020版GOLD指南解读[J]. 诊断学理论与实践, 2020, 19(04): 354-358. |
| [10] | 杜井波, 沈宏华, 许轶明, 任蕾,. 慢性阻塞性肺疾病-阻塞性睡眠呼吸暂停重叠综合征特点分析及康复疗效[J]. 内科理论与实践, 2020, 15(01): 31-37. |
| [11] | 杜云志, 冯菁华, 常春康. 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671. |
| [12] | 陈燕, 李红鹏, 李诗琪, 张柳, 沈继敏, 李庆云,. 冠心病合并阻塞性睡眠呼吸暂停-慢性阻塞性肺疾病重叠综合征1例[J]. 内科理论与实践, 2019, 14(06): 379-380. |
| [13] | 宋元林, 侯东妮. 支气管扩张症患者气道、肠道微生态的研究及临床价值[J]. 诊断学理论与实践, 2019, 18(05): 503-508. |
| [14] | 陈宇清, 王铭杰, 朱东, 吕城坚, 陈萍. 稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的气道阻力对呼出气流受限的影响分析[J]. 诊断学理论与实践, 2019, 18(04): 418-422. |
| [15] | 李蕾, 吴希, 许冠群, 梁茜, 戴菁, 武文漫, 丁秋兰, 王鸿利, 王学锋. 基于新一代测序技术的易栓症基因检测Panel的建立及其在中国静脉血栓患者遗传背景研究中的临床应用[J]. 诊断学理论与实践, 2019, 18(04): 394-401. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
